CORRELATE-UKNCT06898047
Consistency of Response With Rimegepant in Acute Treatment of Migraine
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 9 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Primary and study completion dates changed from estimate of Oct 31, 2026 to Oct 24, 2026
- Notable Eligibility criteria expanded, about 27 words
- Primary and study completion pushed from Jul 31, 2026 to Oct 31, 2026
- Secondary endpoints: details revised at 2 of 3 entries
- Minor Primary completion pushed from Jun 30, 2026 to Jul 31, 2026
- Trial arms changed: 1 → 2
- Secondary endpoints: details revised at 3 of 3 entries
- Minor Study completion date: Jun 30, 2026 to Jul 31, 2026v7
- Minor Trial status: Not Yet Recruiting to Active, Not Recruiting
- Study sites: 0 to 1
- Primary and study completion dates: May 29, 2026 to Jun 30, 2026
- Start date changed from estimate of Sep 17, 2025 to Nov 15, 2025
Show 3 earlier versionsHide 3 earlier versions
- Notable Start date: Aug 1, 2025 to Sep 17, 2025
- Primary and study completion dates: Mar 31, 2026 to May 29, 2026
- Notable Start date: Apr 2025 to Aug 1, 2025
- Primary and study completion dates: Sep 15, 2026 to Mar 31, 2026
- Minor Start date: Mar 31, 2025 to Apr 2025v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time to Meaninful Pain Relief (MPR) post-dosing
Timeframe: Daily (within 24hs post dose)
Secondary (2)
Time to improvement in non-pain symptoms post-dosing
Acute migraine treatment optmization
Arms and interventions
Rimegepant users
Participants with current prescription of rimegepant for acute treatment of migraine
Rimegepant-treated attacks
Migraine attacks treated with rimegepant
Drugs: Rimegepant for acute migraine treatment
Sites
1 site in 1 country
- PfizerLondon, United Kingdom